Orion Group's Annual Report for 2012 has been published. The report is available in Finnish at http://ar2012.orion.fi and in English at http://ar2012.orion.fi/en.
The official financial statement documents, which include the financial statements, the report of the Board of Directors and the auditor's report are available in Finnish at http://www.orion.fi/Orion/Yhtiokokoukset/Yhtiokokous-2013/.
Orion's Corporate Governance Statement for year 2012, adopted by the Board of Directors, is published as a separate report in Finnish at http://www.orion.fi/en/Orion/Corporate-Governance/ and in English at http://www.orion.fi/en/Orion/Corporate-Governance/.
Orion Corporation
Olli Huotari Terhi Ormio
SVP, Corporate Functions VP, Communications
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.